• DE - Deutsch
  • EN - English
  • FR - français
  • IT - italiano
Parliamentary question - E-001917/2021Parliamentary question
E-001917/2021

Novavax vaccine negotiations and transparency

Question for written answer  E-001917/2021
to the Commission
Rule 138
Luisa Regimenti (ID), Marco Campomenosi (ID), Silvia Sardone (ID), Anna Bonfrisco (ID), Elena Lizzi (ID), Matteo Adinolfi (ID), Mara Bizzotto (ID), Stefania Zambelli (ID), Simona Baldassarre (ID), Gunnar Beck (ID), Lucia Vuolo (ID), Julie Lechanteux (ID), Rosanna Conte (ID), Maximilian Krah (ID)

Despite the Commission’s reassurances, the vaccination campaign in Europe is not moving forward as hoped. In view of the late delivery of doses by companies, it would be advisable to diversify purchases in order to secure supplies of different types of vaccine more quickly. One of these, for example, is the product by the Novavax company, which according to Phase 3 studies, is effective against the UK and South African variants.

Yet, while the UK has signed a contract with this US company over the last few days, meaning that the country should be receiving around 50 million doses, the EU negotiations to draw up an advance purchase agreement came to an end in December 2020.

When questioned on this point, Commission spokesperson Ms Loonela merely replied that the EU executive would not provide any details of negotiations under way.

Given that, three months later, there is still no news on the progress of the negotiations and there is a clear public interest in revealing to EU citizens the state of the ongoing talks, can the Commission answer the following questions:

Supporter[1]

Last updated: 26 April 2021
Legal notice - Privacy policy